High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.
Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.
Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.
An AstraZeneca sales executive called the Phase 3 Regal trial a “game changer” for AML patients in their first or second complete remission.
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.
Sellas shares reached a swing high of $15.88 in late June before tumbling 42% to a July low of $9.19.
A German report claimed Regal hit its 80th event, but Sellas has not confirmed it.
The stock has gained over 20% in the past five days, marking its best week since early July.
Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.
Maxim Group described Moderna’s positive late-stage melanoma results as a “win for cancer vaccines,” arguing the surge in Moderna shares should support SELLAS if its key trial succeeds.
Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.
Vanguard held SLS and IBRX positions worth a combined $259 million at quarter-end.
The biotech, focused on novel cancer therapies, reported a net loss of $9.6 million, or $0.05 per share, for the quarter ended June 30.
Wall Street expects no quarterly revenue and a GAAP loss of $0.04 per share, narrowing from $0.05 previously.
Vontobel cut its holding by 16% but retained SLS shares worth $2.17 million.
A new Schedule 13G filing showed Vanguard Capital Management owned 9.67 million SLS shares as of June 30, 2026.
New York State Common Retirement Fund boosted its holding by 70%, while Commonwealth and Axxcess each raised stakes by about 17%.
Sellas estimated cash and cash equivalents of $138.3 million as of June 30.
CEO Angelos Stergiou said recently on “FOX & Friends” that AI and precision medicine could speed drug development and improve patient selection.
During an interview on Fox & Friends on Friday, Stergiou said AI will play a major role in helping cure cancer by enabling more precise treatments.
A new MD Anderson study found that survival was significantly shorter among older and higher-risk AML patients.
Shkreli reiterated his long-standing bearish stance on SLS, although he previously acknowledged making “a bad call” on Capricor after its positive HOPE-3 trial results.
Sellas is preparing for database lock, potential BLA-related regulatory work, and development of SLS009, its second AML drug.
The company entered a quiet period for trial-specific updates ahead of topline data.
Sellas Life Sciences bounced back by 12.26 percent on Friday to close at $13.19 apiece, as investors positioned portfolios ahead of a potentially company-defining clinical data release, supported by takeover speculations and growing institutional interest. The company is expected to report data from the phase 3 study evaluating its Galinpepimut-S (GPS) treatment candidate in patients […]
CEO Angelos Stergiou said he will discuss “novel clinical developments” involving GPS and SLS009 on Fox & Friends.
CEO Angelos M. Stergiou addressed concerns over the company’s trial to treat acute myeloid leukemia.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.